Botanix Founder and Board Executive Director Matt Callahanwill be a featured presenter at the Bell Potter Healthcare Conference 2024 on Tuesday, 19 November. A copy of the presentation being used is attached to the ASX press release.
Ascent Health, second largest Payer (insurer) organisation in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%. Ascent represents approximately 65 million (or nearly 40%) of US commercial lives.
Quarterly Activity Report and 4C Quarterly Cash Flow Report released. At quarter end, Botanix held A$68.67 million cash with no debt (other than typical trade creditors), which will fund operations as it ramps up manufacturing and sales activity of its Sofdra product.
Botanix provides a staffing update as it prepares for the planned launch of Sofdra™ (sofpironium) 12.45% in Q4 CY2024 and announces issuance of its Notice of Meeting for the Annual General Meeting on 4 November 2024 which was released to ASX today.
Botanix CEO Howie McKibbon will be a featured presenter at ASX Small and Mid-Cap Conference on Wednesday, 25 September, and the E&P Small Cap Healthcare Conference on Thursday, 26 September. Botanix will also conduct one-on-one updates with investors.
Click here to view ASX Release.
Join the Botanix commercial team and guests for the Company’s Commercial Day Webinar on Tuesday 17 September 10:30am AEST / 8:30am AWST for a comprehensive update on commercial launch plans and market insights for Sofdra™.
Pre-register: Click here
To view Appendix 4E, click here. Mark your calendar for the Company’s Commercial Day Webinar on
Tuesday 17 September 10:30am AEST / 8:30am AWST which will provide a comprehensive update on
commercial launch plans and market insights for Sofdra™. Registration to follow.
Quarterly Activity Report and 4C Quarterly Cash Flow Report released. At quarter end, Botanix held $79.31 million cash with no debt (other than typical trade creditors), which will fund operations as it ramps up manufacturing and sales activity of its Sofdra product.
Botanix has received firm commitments for $70 million capital raising via an institutional placement. Funds will be applied towards the launch of Sofdra™ (sofpironium) gel, 12.45%, as well as working capital and costs of the placement.
